{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:26:02Z","timestamp":1790810762699,"version":"4.1.0"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genes Genom"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s13258-025-01710-2","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T07:36:47Z","timestamp":1764142607000},"page":"173-184","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Tumor microenvironment-driven drug resistance in urologic cancers: mechanisms and therapeutic targets"],"prefix":"10.1007","volume":"48","author":[{"given":"Gi-Eun","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seo-Yeong","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Seog","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6371-7971","authenticated-orcid":false,"given":"Sun-Hee","family":"Leem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Hyun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"1710_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1453278","author":"M Ahangar","year":"2024","unstructured":"Ahangar M, Mahjoubi F, Mowla SJ (2024) Bladder cancer biomarkers: current approaches and future directions. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2024.1453278","journal-title":"Front Oncol"},{"key":"1710_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/nrurol.2015.292","volume":"13","author":"M Alfano","year":"2016","unstructured":"Alfano M, Canducci F, Nebuloni M, Clementi M, Montorsi F, Salonia A (2016) The interplay of extracellular matrix and microbiome in urothelial bladder cancer. Nat Rev Urol 13:77\u201390","journal-title":"Nat Rev Urol"},{"key":"1710_CR3","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.ccell.2021.10.001","volume":"39","author":"L Au","year":"2021","unstructured":"Au L, Hatipoglu E, de Massy MR, Litchfield K, Beattie G, Rowan A, Schnidrig D, Thompson R, Byrne F, Horswell S et al (2021) Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell 39:1497","journal-title":"Cancer Cell"},{"key":"1710_CR4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI164249","author":"ZA Bacigalupa","year":"2024","unstructured":"Bacigalupa ZA, Arner EN, Vlach LM, Wolf MM, Brown WA, Krystofiak ES, Ye X, Hongo RA, Landis M, Amason EK et al (2024) HIF-2\u03b1 expression and metabolic signaling require ACSS2 in clear cell renal cell carcinoma. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI164249","journal-title":"J Clin Invest"},{"key":"1710_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.652747","author":"HF Bahmad","year":"2021","unstructured":"Bahmad HF, Jalloul M, Azar J, Moubarak MM, Samad TA, Mukherji D, Al-Sayegh M, Abou-Kheir W (2021) Tumor microenvironment in prostate cancer: toward identification of novel molecular biomarkers for diagnosis, prognosis, and therapy development. Front Genet. https:\/\/doi.org\/10.3389\/fgene.2021.652747","journal-title":"Front Genet"},{"key":"1710_CR6","first-page":"401","volume":"20","author":"P Banerjee","year":"2023","unstructured":"Banerjee P, Kapse P, Siddique S, Kundu M, Choudhari J, Mohanty V, Malhotra D, Gosavi SW, Gacche RN, Kundu GC (2023) Therapeutic implications of cancer stem cells in prostate cancer. Cancer Biol Med 20:401\u2013420","journal-title":"Cancer Biol Med"},{"key":"1710_CR7","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle E, Massague J (2019) Transforming growth factor-beta signaling in immunity and cancer. Immunity 50:924\u2013940","journal-title":"Immunity"},{"key":"1710_CR8","doi-asserted-by":"publisher","first-page":"5724","DOI":"10.3390\/cancers13225724","volume":"13","author":"DJ Benjamin","year":"2021","unstructured":"Benjamin DJ, Lyou Y (2021a) Advances in immunotherapy and the TGF-beta resistance pathway in metastatic bladder cancer. Cancers (Basel) 13:5724","journal-title":"Cancers (Basel)"},{"key":"1710_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225724","author":"DJ Benjamin","year":"2021","unstructured":"Benjamin DJ, Lyou Y (2021b) Advances in immunotherapy and the TGF-\u03b2 resistance pathway in metastatic bladder cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13225724","journal-title":"Cancers (Basel)"},{"key":"1710_CR10","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/MOU.0000000000000987","volume":"32","author":"RC Borges","year":"2022","unstructured":"Borges RC, Tourinho-Barbosa RR, de la Rosette J (2022) Tumour microenvironment and focal therapy for prostate cancer. Curr Opin Urol 32:248\u2013253","journal-title":"Curr Opin Urol"},{"key":"1710_CR11","doi-asserted-by":"publisher","first-page":"6995","DOI":"10.3390\/ijms22136995","volume":"22","author":"AJ Boutilier","year":"2021","unstructured":"Boutilier AJ, Elsawa SF (2021) Macrophage polarization states in the tumor microenvironment. Int J Mol Sci 22:6995","journal-title":"Int J Mol Sci"},{"key":"1710_CR12","first-page":"14","volume":"22","author":"KK Brodaczewska","year":"2018","unstructured":"Brodaczewska KK, Szczylik C, Kieda C (2018) Immune consequences of anti-angiogenic therapyin renal cell carcinoma. Contemp Oncol (Pozn) 22:14\u201322","journal-title":"Contemp Oncol (Pozn)"},{"key":"1710_CR13","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2147\/ITT.S291767","volume":"10","author":"R Bughda","year":"2021","unstructured":"Bughda R, Dimou P, D\u2019Souza RR, Klampatsa A (2021) Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: launching an attack on tumor stroma. Immunotargets Ther 10:313\u2013323","journal-title":"Immunotargets Ther"},{"key":"1710_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06654-8","author":"A Chakravarthy","year":"2018","unstructured":"Chakravarthy A, Khan L, Bensler NP, Bose P, De Carvalho DD (2018) TGF-\u03b2-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-018-06654-8","journal-title":"Nat Commun"},{"key":"1710_CR15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1681\/ASN.2011070645","volume":"23","author":"JC Chen","year":"2012","unstructured":"Chen JC, Chen JK, Nagai K, Plieth D, Tan MQ, Lee TC, Threadgill DW, Neilson EG, Harris RC (2012) EGFR signaling promotes TGF\u03b2-dependent renal fibrosis. J Am Soc Nephrol 23:215\u2013224","journal-title":"J Am Soc Nephrol"},{"key":"1710_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41389-019-0121-7","volume":"8","author":"CH Chen","year":"2019","unstructured":"Chen CH, Bhasin S, Khanna P, Joshi M, Joslin PM, Saxena R, Amin S, Liu S, Sindhu S, Walker SR et al (2019) Study of cathepsin B inhibition in VEGFR TKI treated human renal cell carcinoma xenografts. Oncogenesis 8:15","journal-title":"Oncogenesis"},{"key":"1710_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2217\/epi-2023-0358","volume":"16","author":"JQ Chen","year":"2024","unstructured":"Chen JQ, Salas LA, Wiencke JK, Koestler DC, Molinaro AM, Andrew AS, Seigne JD, Karagas MR, Kelsey KT, Christensen BC (2024a) Matched analysis of detailed peripheral blood and tumor immune microenvironment profiles in bladder cancer. Epigenomics 16:41\u201356","journal-title":"Epigenomics"},{"key":"1710_CR18","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s12094-023-03270-x","volume":"26","author":"X Chen","year":"2024","unstructured":"Chen X, Liao CY, Zou X, Zhang B, Mo ZN (2024b) A gene signature of cancer-associated fibroblasts predicts prognosis and treatment response in bladder cancer. Clin Transl Oncol 26:477\u2013495","journal-title":"Clin Transl Oncol"},{"key":"1710_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13046-024-02962-8","volume":"43","author":"BS Cheng","year":"2024","unstructured":"Cheng BS, Li LF, Luo TL, Wang Q, Luo Y, Bai SM, Li KW, Lai YM, Huang H (2024a) Single-cell deconvolution algorithms analysis unveils autocrine IL11-mediated resistance to docetaxel in prostate cancer via activation of the JAK1\/STAT4 pathway. J Exp Clin Cancer Res 43:67","journal-title":"J Exp Clin Cancer Res"},{"key":"1710_CR20","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1038\/s12276-023-01114-w","volume":"55","author":"Y Choi","year":"2023","unstructured":"Choi Y, Jung K (2023) Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy. Exp Mol Med 55:2308\u20132319","journal-title":"Exp Mol Med"},{"key":"1710_CR21","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","volume":"27","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, Michaelson MD, Appleman LJ, Thamake S, Perini RF et al (2021a) Inhibition of hypoxia-inducible factor-2\u03b1 in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat Med 27:802","journal-title":"Nat Med"},{"key":"1710_CR22","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Ju\u00e1rez VMO, Hsieh JJ, Basso U, Shah AY et al (2021b) Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 384:829\u2013841","journal-title":"N Engl J Med"},{"key":"1710_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13195738","author":"S Compagno","year":"2024","unstructured":"Compagno S, Casadio C, Galvani L, Rosellini M, Marchetti A, Tassinari E, Piazza P, Mottaran A, Santoni M, Schiavina R et al (2024) Novel immune checkpoint inhibitor targets in advanced or metastatic renal cell carcinoma: state of the art and future perspectives. J Clin Med. https:\/\/doi.org\/10.3390\/jcm13195738","journal-title":"J Clin Med"},{"key":"1710_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116203","author":"JW Cui","year":"2024","unstructured":"Cui JW, Li Y, Yang Y, Yang HK, Dong JM, Xiao ZH, He X, Guo JH, Wang RQ, Dai B et al (2024) Tumor immunotherapy resistance: revealing the mechanism of PD-1 \/ PD-L1-mediated tumor immune escape. Biomed Pharmacother. https:\/\/doi.org\/10.1016\/j.biopha.2024.116203","journal-title":"Biomed Pharmacother"},{"key":"1710_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01764-w","author":"ZQ Deng","year":"2024","unstructured":"Deng ZQ, Fan T, Xiao C, Tian H, Zheng YJ, Li CX, He J (2024) TGF-\u03b2 signaling in health, disease, and therapeutics. Signal Transduct Target Ther. https:\/\/doi.org\/10.1038\/s41392-024-01764-w","journal-title":"Signal Transduct Target Ther"},{"key":"1710_CR26","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.lfs.2010.02.012","volume":"86","author":"XW Ding","year":"2010","unstructured":"Ding XW, Wu JH, Jiang CP (2010) ABCG2: a potential marker of stem cells and novel target in stern cell and cancer therapy. Life Sci 86:631\u2013637","journal-title":"Life Sci"},{"key":"1710_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-024-03081-0","author":"V Doldi","year":"2024","unstructured":"Doldi V, Tortoreto M, Colecchia M, Maffezzini M, Percio S, Giammello F, Brandalise F, Gandellini P, Zaffaroni N (2024) Repositioning of antiarrhythmics for prostate cancer treatment: a novel strategy to reprogram cancer-associated fibroblasts towards a tumor-suppressive phenotype. J Exp Clin Cancer Res. https:\/\/doi.org\/10.1186\/s13046-024-03081-0","journal-title":"J Exp Clin Cancer Res"},{"key":"1710_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.immuni.2011.04.019","volume":"35","author":"MK Donkor","year":"2011","unstructured":"Donkor MK, Sarkar A, Savage PA, Franklin RA, Johnson LK, Jungbluth AA, Allison JP, Li MO (2011) T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-\u03b21 cytokine. Immunity 35:123\u2013134","journal-title":"Immunity"},{"key":"1710_CR29","doi-asserted-by":"publisher","first-page":"5739","DOI":"10.1038\/s41596-021-00494-5","volume":"16","author":"E Driehuis","year":"2021","unstructured":"Driehuis E, Kretzschmar K, Clevers H (2021) Establishment of patient-derived cancer organoids for drug-screening applications (vol 63, pg 891, 2020). Nat Protoc 16:5739\u20135739","journal-title":"Nat Protoc"},{"key":"1710_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071534","author":"M Ehsani","year":"2021","unstructured":"Ehsani M, David FO, Baniahmad A (2021) Androgen receptor-dependent mechanisms mediating drug resistance in prostate cancer. Cancers. https:\/\/doi.org\/10.3390\/cancers13071534","journal-title":"Cancers"},{"key":"1710_CR31","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1042\/BST20160387","volume":"45","author":"B Erdogan","year":"2017","unstructured":"Erdogan B, Webb DJ (2017) Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis. Biochem Soc Trans 45:229\u2013236","journal-title":"Biochem Soc Trans"},{"key":"1710_CR32","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1158\/0008-5472.CAN-14-0992","volume":"75","author":"J Escamilla","year":"2015","unstructured":"Escamilla J, Schokrpur S, Liu CN, Priceman SJ, Moughon D, Jiang ZY, Pouliot F, Magyar C, Sung JL, Xu JY et al (2015) CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy. Cancer Res 75:950\u2013962","journal-title":"Cancer Res"},{"key":"1710_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1467602","author":"XQ Feng","year":"2024","unstructured":"Feng XQ, Cao FJ, Wu XJ, Xie WY, Wang P, Jiang H (2024) Targeting extracellular matrix stiffness for cancer therapy. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2024.1467602","journal-title":"Front Immunol"},{"key":"1710_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00272-w","author":"RB Ge","year":"2022","unstructured":"Ge RB, Wang ZW, Cheng L (2022) Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance. NPJ Precis Oncol. https:\/\/doi.org\/10.1038\/s41698-022-00272-w","journal-title":"NPJ Precis Oncol"},{"key":"1710_CR35","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","volume":"120","author":"C Groth","year":"2019","unstructured":"Groth C, Hu XY, Weber R, Fleming V, Altevogt P, Utikal J, Umansky V (2019) Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer 120:16\u201325","journal-title":"Br J Cancer"},{"key":"1710_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/genes12050773","author":"W Guan","year":"2021","unstructured":"Guan W, Li F, Zhao ZY, Zhang ZB, Hu JH, Zhang Y (2021) Tumor-associated macrophage promotes the survival of cancer cells upon docetaxel chemotherapy via the CSF1\/CSF1R-CXCL12\/CXCR4 axis in castration-resistant prostate cancer. Genes. https:\/\/doi.org\/10.3390\/genes12050773","journal-title":"Genes"},{"key":"1710_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14246167","author":"Z Guillaume","year":"2022","unstructured":"Guillaume Z, Auvray M, Vano Y, Oudard S, Helley D, Mauge L (2022) Renal carcinoma and angiogenesis: therapeutic target and biomarkers of response in current therapies. Cancers. https:\/\/doi.org\/10.3390\/cancers14246167","journal-title":"Cancers"},{"key":"1710_CR38","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1158\/2159-8290.CD-18-0957","volume":"9","author":"AA Hakimi","year":"2019","unstructured":"Hakimi AA, Voss MH, Kuo FS, Sanchez A, Liu M, Nixon BG, Vuong L, Ostrovnaya I, Chen YB, Reuter V et al (2019) Transcriptomic profiling of the tumor microenvironment reveals distinct subgroups of clear cell renal cell cancer: data from a randomized phase III trial. Cancer Discov 9:510\u2013525","journal-title":"Cancer Discov"},{"key":"1710_CR39","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1158\/2326-6066.CIR-14-0193","volume":"2","author":"LC Harshman","year":"2014","unstructured":"Harshman LC, Drake CG, Choueiri TK (2014) PD-1 blockade in renal cell carcinoma: to equilibrium and beyond. Cancer Immunol Res 2:1132\u20131141","journal-title":"Cancer Immunol Res"},{"key":"1710_CR40","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/978-3-030-59038-3_17","volume":"1296","author":"K Hatogai","year":"2020","unstructured":"Hatogai K, Sweis RF (2020) The tumor microenvironment of bladder cancer. Tumor Microenviron Organs 1296:275\u2013290","journal-title":"Tumor Microenviron Organs"},{"key":"1710_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2019.00160","author":"E Henke","year":"2020","unstructured":"Henke E, Nandigama R, Erg\u00fcn S (2020) Extracellular matrix in the tumor microenvironment and its impact on cancer therapy. Front Mol Biosci. https:\/\/doi.org\/10.3389\/fmolb.2019.00160","journal-title":"Front Mol Biosci"},{"key":"1710_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0356-4","author":"RB Holmgaard","year":"2018","unstructured":"Holmgaard RB, Schaer DA, Li YX, Castaneda SP, Murphy MY, Xu XH, Inigo I, Dobkin J, Manro JR, Iversen PW et al (2018) Targeting the TGF\u03b2 pathway with galunisertib, a TGF\u03b2RI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. J Immunother Cancer. https:\/\/doi.org\/10.1186\/s40425-018-0356-4","journal-title":"J Immunother Cancer"},{"key":"1710_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70299","author":"R Hong","year":"2025","unstructured":"Hong R, Yu PG, Zhang XL, Su P, Liang HY, Dong D, Wang XS, Wang KF (2025) The role of cancer-associated fibroblasts in the tumour microenvironment of urinary system. Clin Transl Med. https:\/\/doi.org\/10.1002\/ctm2.70299","journal-title":"Clin Transl Med"},{"key":"1710_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.9","author":"JJ Hsieh","year":"2017","unstructured":"Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V (2017) Renal cell carcinoma. Nat Rev Dis Primers. https:\/\/doi.org\/10.1038\/nrdp.2017.9","journal-title":"Nat Rev Dis Primers"},{"key":"1710_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217339","author":"MS Jeong","year":"2025","unstructured":"Jeong MS, Baek SW, Yang GE, Mun JY, Kim JA, Kim TN, Nam JK, Choi YH, Lee JS, Chu IS et al (2025) Chemoresistance-motility signature of molecular evolution to chemotherapy in non-muscle-invasive bladder cancer and its clinical implications. Cancer Lett. https:\/\/doi.org\/10.1016\/j.canlet.2024.217339","journal-title":"Cancer Lett"},{"key":"1710_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.639636","author":"YL Jian","year":"2021","unstructured":"Jian YL, Yang KK, Sun XX, Zhao J, Huang K, Aldanakh A, Xu ZY, Wu HT, Xu QW, Zhang L et al (2021) Current advance of immune evasion mechanisms and emerging immunotherapies in renal cell carcinoma. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2021.639636","journal-title":"Front Immunol"},{"issue":"4","key":"1710_CR47","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun A, de Reynies A, Allory Y, Sjodahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, Zlotta A, Hartmann A, Dinney CP, Bellmunt J, Powles T, Malats N, Chan KS, Kim WY, McConkey DJ, Black PC, Dyrskj\u00f8t L, H\u00f6glund M, Lerner SP, Real FX, Radvanyi F, Bladder Cancer Molecular Taxonomy Group (2020) A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol 77(4):420\u2013433. https:\/\/doi.org\/10.1016\/j.eururo.2019.09.006","journal-title":"Eur Urol"},{"key":"1710_CR48","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/cancers16010022","volume":"16","author":"AA Khan","year":"2024","unstructured":"Khan AA, Al-Mahrouqi N, Al-Yahyaee A, Al-Sayegh H, Al-Harthy M, Al-Zadjali S (2024) Deciphering urogenital cancers through proteomic biomarkers: a systematic review and meta-analysis. Cancers 16:22","journal-title":"Cancers"},{"key":"1710_CR49","doi-asserted-by":"publisher","first-page":"148","DOI":"10.5152\/tud.2024.24024","volume":"50","author":"S Kianmehr","year":"2024","unstructured":"Kianmehr S, Vahabirad M, Seghatoleslam A, Sadeghi E, Kiani R, Ghasemi H (2024) Prognostic value of TGF-beta expression in bladder cancer: a systematic review and meta-analysis. Urol Res Pract 50:148\u2013153","journal-title":"Urol Res Pract"},{"key":"1710_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/cells13211779","author":"C Klein","year":"2024","unstructured":"Klein C, Mebroukine S, Mad\u00e9ry M, Moisand A, Boyer T, Larmonier N, Robert G, Domblides C (2024) Myeloid-derived suppressor cells in bladder cancer: an emerging target. Cells. https:\/\/doi.org\/10.3390\/cells13211779","journal-title":"Cells"},{"key":"1710_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071064","author":"WA Kwon","year":"2025","unstructured":"Kwon WA, Joung JY (2025) Immunotherapy in prostate cancer: from a \u201cCold\u201d tumor to a \u201cHot\u201d prospect. Cancers. https:\/\/doi.org\/10.3390\/cancers17071064","journal-title":"Cancers"},{"key":"1710_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11041071","author":"F Lasorsa","year":"2023","unstructured":"Lasorsa F, di Meo NA, Rutigliano M, Milella M, Ferro M, Pandolfo SD, Crocetto F, Tataru OS, Autorino R, Battaglia M et al (2023) Immune checkpoint inhibitors in renal cell carcinoma: molecular basis and rationale for their use in clinical practice. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines11041071","journal-title":"Biomedicines"},{"key":"1710_CR53","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1158\/2326-6066.CIR-19-0826","volume":"8","author":"MM Leblond","year":"2020","unstructured":"Leblond MM, Till\u00e9 L, Nassiri S, Gilfillan CB, Imbratta C, Schmittnaegel M, Ries CH, Speiser DE, Verdeil G (2020) CD40 agonist restores the antitumor efficacy of anti-PD1 therapy in muscle-invasive bladder cancer in an IFN I\/II-mediated manner. Cancer Immunol Res 8:1180\u20131192","journal-title":"Cancer Immunol Res"},{"key":"1710_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141589","author":"E Lee","year":"2015","unstructured":"Lee E, Ha S, Logan SK (2015) Divergent androgen receptor and beta-catenin signaling in prostate cancer cells. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0141589","journal-title":"PLoS ONE"},{"key":"1710_CR55","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41585-022-00608-y","volume":"19","author":"YC Lee","year":"2022","unstructured":"Lee YC, Lam HM, Rosser C, Theodorescu D, Parks WC, Chan KS (2022) The dynamic roles of the bladder tumour microenvironment. Nat Rev Urol 19:515\u2013533","journal-title":"Nat Rev Urol"},{"key":"1710_CR56","doi-asserted-by":"publisher","first-page":"956","DOI":"10.3724\/abbs.2023092","volume":"55","author":"DC Li","year":"2023","unstructured":"Li DC, Xu WD, Chang YF, Xiao YT, He YD, Ren SC (2023a) Advances in landscape and related therapeutic targets of the prostate tumor microenvironment. Acta Biochim Biophys Sin 55:956\u2013973","journal-title":"Acta Biochim Biophys Sin"},{"key":"1710_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-44028-3","author":"YF Li","year":"2023","unstructured":"Li YF, Liu Y, Kang ZJ, Guo JH, Liu N (2023b) Tumor microenvironment heterogeneity in bladder cancer identifies biologically distinct subtypes predicting prognosis and anti-PD-L1 responses. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-023-44028-3","journal-title":"Sci Rep"},{"key":"1710_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202303230","author":"T Liang","year":"2023","unstructured":"Liang T, Tao T, Wu K, Liu LS, Xu WW, Zhou DW, Fang H, Ding QX, Huang GX, Wu S (2023) Cancer-associated fibroblast-induced remodeling of tumor microenvironment in recurrent bladder cancer. Adv Sci. https:\/\/doi.org\/10.1002\/advs.202303230","journal-title":"Adv Sci"},{"key":"1710_CR59","doi-asserted-by":"publisher","first-page":"233","DOI":"10.4103\/aja.aja_72_18","volume":"21","author":"CJ Lin","year":"2019","unstructured":"Lin CJ, Lo UG, Hsieh JT (2019) The regulatory pathways leading to stem-like cells underlie prostate cancer progression. Asian J Androl 21:233\u2013240","journal-title":"Asian J Androl"},{"key":"1710_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.653358","author":"EY Lin","year":"2021","unstructured":"Lin EY, Liu XC, Liu YJ, Zhang ZD, Xie L, Tian KW, Liu JM, Yu YM (2021) Roles of the dynamic tumor immune microenvironment in the individualized treatment of advanced clear cell renal cell carcinoma. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2021.653358","journal-title":"Front Immunol"},{"key":"1710_CR61","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000433","author":"H Lind","year":"2020","unstructured":"Lind H, Gameiro SR, Jochems C, Donahue RN, Strauss J, Gulley JL, Palena C, Schlom J (2020) Dual targeting of TGF-\u03b2 and PD-L1 via a bifunctional anti-PD-L1\/TGF-\u03b2RII agent: status of preclinical and clinical advances. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2019-000433","journal-title":"J Immunother Cancer"},{"key":"1710_CR62","first-page":"E222","volume":"203","author":"J Linxweiler","year":"2020","unstructured":"Linxweiler J, Zaccagnino A, Himbert D, Hajili T, Zeuschner P, K\u00f6rbel C, St\u00f6ckle M, Menger MD, Saar M, Junker K (2020) The role of cancer-associated fibroblasts and their extracellular vesicles in prostate cancer progression. J Urol 203:E222\u2013E222","journal-title":"J Urol"},{"key":"1710_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-024-03164-y","author":"H Liu","year":"2024","unstructured":"Liu H, Lv ZW, Zhang G, Yan ZH, Bai S, Dong D, Wang KF (2024) Molecular understanding and clinical aspects of tumor-associated macrophages in the immunotherapy of renal cell carcinoma. J Exp Clin Cancer Res. https:\/\/doi.org\/10.1186\/s13046-024-03164-y","journal-title":"J Exp Clin Cancer Res"},{"key":"1710_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14122887","author":"C Luthold","year":"2022","unstructured":"Luthold C, Hallal T, Labb\u00e9 DP, Bordeleau F (2022) The extracellular matrix stiffening: a trigger of prostate cancer progression and castration resistance? Cancers. https:\/\/doi.org\/10.3390\/cancers14122887","journal-title":"Cancers"},{"key":"1710_CR65","doi-asserted-by":"publisher","first-page":"1418131","DOI":"10.3389\/fimmu.2024.1418131","volume":"15","author":"YC Ma","year":"2024","unstructured":"Ma YC, Sun Y, Guo HQ, Yang R (2024) Tumor-associated macrophages in bladder cancer: roles and targeted therapeutic strategies. Front Immunol 15:1418131","journal-title":"Front Immunol"},{"key":"1710_CR66","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang YL, Kadel E, Koeppen H, Astarita JL, Cubas R et al (2018) TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554:544","journal-title":"Nature"},{"key":"1710_CR67","doi-asserted-by":"publisher","first-page":"7388","DOI":"10.1158\/1078-0432.CCR-17-1004","volume":"23","author":"VG Mart\u00ednez","year":"2017","unstructured":"Mart\u00ednez VG, Rubio C, Mart\u00ednez-Fern\u00e1ndez M, Segovia C, L\u00f3pez-Calder\u00f3n F, Garin MI, Teijeira A, Munera-Maravilla E, Varas A, Saced\u00f3n R et al (2017) BMP4 induces M2 macrophage polarization and favors tumor progression in bladder cancer. Clin Cancer Res 23:7388\u20137399","journal-title":"Clin Cancer Res"},{"key":"1710_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041316","author":"S Mazumder","year":"2023","unstructured":"Mazumder S, Higgins PJ, Samarakoon R (2023) Downstream targets of VHL\/HIF-\u03b1 signaling in renal clear cell carcinoma progression: mechanisms and therapeutic relevance. Cancers. https:\/\/doi.org\/10.3390\/cancers15041316","journal-title":"Cancers"},{"key":"1710_CR69","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/CCO.0000000000000512","volume":"31","author":"JW Mier","year":"2019","unstructured":"Mier JW (2019) The tumor microenvironment in renal cell cancer. Curr Opin Oncol 31:194\u2013199","journal-title":"Curr Opin Oncol"},{"key":"1710_CR70","doi-asserted-by":"publisher","DOI":"10.48101\/ujms.v129.10710","author":"V Milosevic","year":"2024","unstructured":"Milosevic V, \u00d6stman A (2024) Interactions between cancer-associated fibroblasts and T-cells: functional crosstalk with targeting and biomarker potential. Ups J Med Sci. https:\/\/doi.org\/10.48101\/ujms.v129.10710","journal-title":"Ups J Med Sci"},{"key":"1710_CR71","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.euros.2024.06.011","volume":"66","author":"T Muilwijk","year":"2024","unstructured":"Muilwijk T, Baekelandt L, Akand M, Daelemans S, Marien K, Waumans Y, van Dam PJ, Kockx M, van den Broeck T, Van Cleynenbreugel B et al (2024) Fibroblast activation protein-\u03b1 and the immune landscape: unraveling T1 non-muscle-invasive bladder cancer progression. Eur Urol Open Sci 66:67\u201374","journal-title":"Eur Urol Open Sci"},{"key":"1710_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-022-01242-8","author":"JY Mun","year":"2022","unstructured":"Mun JY, Baek SW, Jeong MS, Jang IH, Lee SR, You JY, Kim JA, Yang GE, Choi YH, Kim TN et al (2022) Stepwise molecular mechanisms responsible for chemoresistance in bladder cancer cells. Cell Death Discov. https:\/\/doi.org\/10.1038\/s41420-022-01242-8","journal-title":"Cell Death Discov"},{"key":"1710_CR73","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2174\/1568009614666140328152459","volume":"14","author":"J Ni","year":"2014","unstructured":"Ni J, Cozzi P, Hao JL, Duan W, Graham P, Kearsley J, Li Y (2014) Cancer stem cells in prostate cancer chemoresistance. Curr Cancer Drug Targets 14:225\u2013240","journal-title":"Curr Cancer Drug Targets"},{"key":"1710_CR74","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s11307-022-01715-3","volume":"24","author":"E Novruzov","year":"2022","unstructured":"Novruzov E, Dendl K, Ndlovu H, Choyke PL, Dabir M, Beu M, Novruzov F, Mehdi E, Guliyev F, Koerber SA et al (2022) Head-to-head Intra-individual comparison of [Ga]-FAPI and [F]-FDG PET\/CT in patients with bladder cancer. Mol Imaging Biol 24:651\u2013658","journal-title":"Mol Imaging Biol"},{"key":"1710_CR75","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.2217\/imt-2023-0218","volume":"15","author":"G Nuvola","year":"2023","unstructured":"Nuvola G, Mollica V, Massari F, Suarez C (2023) The future of immunotherapy in advanced renal cell carcinoma: beyond PD-1\/PD-L1 inhibitors. Immunotherapy 15:1429\u20131433","journal-title":"Immunotherapy"},{"key":"1710_CR76","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/pros.23708","volume":"79","author":"C Paller","year":"2019","unstructured":"Paller C, Pu H, Begemann DE, Wade CA, Hensley PJ, Kyprianou N (2019) TGF-\u03b2 receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer. Prostate 79:31\u201343","journal-title":"Prostate"},{"key":"1710_CR77","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12943-021-01426-3","volume":"20","author":"S Pamarthy","year":"2021","unstructured":"Pamarthy S, Sabaawy HE (2021) Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine. Mol Cancer 20:125","journal-title":"Mol Cancer"},{"key":"1710_CR78","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/s41416-022-02085-x","volume":"128","author":"F Pederzoli","year":"2023","unstructured":"Pederzoli F, Raffo M, Pakula H, Ravera F, Nuzzo PV, Loda M (2023) Stromal cells in prostate cancer pathobiology: friends or foes? Br J Cancer 128:930\u2013939","journal-title":"Br J Cancer"},{"key":"1710_CR79","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s10020-023-00665-y","volume":"29","author":"ZW Peng","year":"2023","unstructured":"Peng ZW, Tong ZW, Ren ZH, Ye MP, Hu KW (2023) Cancer-associated fibroblasts and its derived exosomes: a new perspective for reshaping the tumor microenvironment. Mol Med 29:66","journal-title":"Mol Med"},{"key":"1710_CR80","doi-asserted-by":"publisher","first-page":"9016","DOI":"10.1038\/s41598-023-36125-0","volume":"13","author":"YL Qian","year":"2023","unstructured":"Qian YL, Feng DC, Wang J, Wei WR, Wei Q, Han P, Yang L (2023) Establishment of cancer-associated fibroblasts-related subtypes and prognostic index for prostate cancer through single-cell and bulk RNA transcriptome. Sci Rep 13:9016","journal-title":"Sci Rep"},{"key":"1710_CR81","first-page":"211","volume":"17","author":"A Quistini","year":"2025","unstructured":"Quistini A, Chierigo F, Fallara G, Depalma M, Tozzi M, Maggi M, Jannello LMI, Pellegrino F, Mantica G, Terracciano D et al (2025) Androgen receptor signalling in prostate cancer: mechanisms of resistance to endocrine therapies. Res Rep Urol 17:211\u2013223","journal-title":"Res Rep Urol"},{"key":"1710_CR82","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1586\/14737140.8.1.63","volume":"8","author":"WK Rathmell","year":"2008","unstructured":"Rathmell WK, Chen S (2008) Inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. Expert Rev Anticancer Ther 8:63\u201373","journal-title":"Expert Rev Anticancer Ther"},{"key":"1710_CR83","doi-asserted-by":"publisher","first-page":"741s","DOI":"10.1158\/1078-0432.CCR-06-2110","volume":"13","author":"BI Rini","year":"2007","unstructured":"Rini BI, Rathmell WK (2007) Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma. Clin Cancer Res 13:741s\u2013746s","journal-title":"Clin Cancer Res"},{"key":"1710_CR84","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, Fearon D, Greten FR, Hingorani SR, Hunter T et al (2020) A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer 20:174\u2013186","journal-title":"Nat Rev Cancer"},{"key":"1710_CR85","doi-asserted-by":"publisher","first-page":"416","DOI":"10.20517\/cdr.2023.02","volume":"6","author":"S Samnani","year":"2023","unstructured":"Samnani S, Sachedina F, Gupta M, Guo E, Navani V (2023) Mechanisms and clinical implications in renal carcinoma resistance: narrative review of immune checkpoint inhibitors. Cancer Drug Resist 6:416\u2013429","journal-title":"Cancer Drug Resist"},{"key":"1710_CR86","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s00262-013-1487-6","volume":"62","author":"M Santoni","year":"2013","unstructured":"Santoni M, Massari F, Amantini C, Nabissi M, Maines F, Burattini L, Berardi R, Santoni G, Montironi R, Tortora G et al (2013) Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 62:1757\u20131768","journal-title":"Cancer Immunol Immunother"},{"key":"1710_CR87","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.3390\/ijms18122627","volume":"18","author":"G Schepisi","year":"2017","unstructured":"Schepisi G, Farolfi A, Conteduca V, Martignano F, De Lisi D, Ravaglia G, Rossi L, Menna C, Bellia SR, Barone D et al (2017) Immunotherapy for prostate cancer: where we are headed. Int J Mol Sci 18:2627","journal-title":"Int J Mol Sci"},{"key":"1710_CR88","doi-asserted-by":"publisher","first-page":"e36839","DOI":"10.1016\/j.heliyon.2024.e36839","volume":"10","author":"YC Shao","year":"2024","unstructured":"Shao YC, Han S, Hou ZX, Yang C, Zhao YB (2024) Tumor-associated macrophages within the immunological milieu: an emerging focal point for therapeutic intervention. Heliyon 10:e36839","journal-title":"Heliyon"},{"key":"1710_CR89","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.3390\/cancers15092500","volume":"15","author":"DD Shapiro","year":"2023","unstructured":"Shapiro DD, Dolan B, Laklouk IA, Rassi S, Lozar T, Emamekhoo H, Wentland AL, Lubner MG, Abel EJ (2023) Understanding the tumor immune microenvironment in renal cell carcinoma. Cancers (Basel) 15:2500","journal-title":"Cancers (Basel)"},{"key":"1710_CR114","doi-asserted-by":"publisher","unstructured":"Shi ZD, Sun Z, Zhu ZB, Liu X, Chen JZ, Hao L, Zhu JF, Pang K, Wu D, Dong Y, Liu YF (2023) Integrated single-cell and spatial transcriptomic profiling reveals higher intratumour heterogeneity and epithelial\u2013fibroblast interactions in recurrent bladder cancer. Clin Transl Med 13(7):e1338. https:\/\/doi.org\/10.1002\/ctm2.1338","DOI":"10.1002\/ctm2.1338"},{"key":"1710_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25063105","author":"J Shin","year":"2024","unstructured":"Shin J, Park JW, Kim SY, Lee JH, Choi WS, Kim HS (2024) Strategies for overcoming immune evasion in bladder cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25063105","journal-title":"Int J Mol Sci"},{"key":"1710_CR91","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1158\/0008-5472.CAN-12-2799","volume":"73","author":"AG Sowalsky","year":"2013","unstructured":"Sowalsky AG, Ye HH, Bubley GJ, Balk SP (2013) Clonal progression of prostate cancers from Gleason grade 3 to grade 4. Cancer Res 73:1050\u20131055","journal-title":"Cancer Res"},{"key":"1710_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/medsci11030046","author":"C Suarez","year":"2023","unstructured":"Suarez C, Vieito M, Valdivia A, Gonzalez M, Carles J (2023) Selective HIF2A inhibitors in the management of clear cell renal cancer and Von Hippel-Lindau-disease-associated tumors. Med Sci. https:\/\/doi.org\/10.3390\/medsci11030046","journal-title":"Med Sci"},{"key":"1710_CR93","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/nm.2890","volume":"18","author":"Y Sun","year":"2012","unstructured":"Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, True L, Nelson PS (2012) Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med 18:1359","journal-title":"Nat Med"},{"key":"1710_CR94","doi-asserted-by":"publisher","first-page":"858","DOI":"10.20517\/cdr.2023.89","volume":"6","author":"PL Sweeney","year":"2023","unstructured":"Sweeney PL, Suri Y, Basu A, Koshkin VS, Desai A (2023) Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma. Cancer Drug Resist 6:858\u2013873","journal-title":"Cancer Drug Resist"},{"key":"1710_CR95","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-00902-8","author":"L Tang","year":"2024","unstructured":"Tang L, Xu HF, Wu T, Wu WH, Lu YH, Gu JJ, Wang XL, Zhou M, Chen QY, Sun X et al (2024) Advances in tumor microenvironment and underlying molecular mechanisms of bladder cancer: a systematic review. Discov Oncol. https:\/\/doi.org\/10.1007\/s12672-024-00902-8","journal-title":"Discov Oncol"},{"key":"1710_CR96","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1158\/1535-7163.MCT-10-0470","volume":"9","author":"CB Thompson","year":"2010","unstructured":"Thompson CB, Shepard HM, O\u2019Connor PM, Kadhim S, Jiang P, Osgood RJ, Bookbinder LH, Li XM, Sugarman BJ, Connor RJ et al (2010) Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol Cancer Ther 9:3052\u20133064","journal-title":"Mol Cancer Ther"},{"key":"1710_CR97","first-page":"318","volume":"9","author":"B Thompson-Elliott","year":"2021","unstructured":"Thompson-Elliott B, Johnson R, Khan SA (2021) Alterations in TGFbeta signaling during prostate cancer progression. Am J Clin Exp Urol 9:318\u2013328","journal-title":"Am J Clin Exp Urol"},{"key":"1710_CR98","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/17512433.2024.2436433","volume":"18","author":"A Vald\u00e9s","year":"2025","unstructured":"Vald\u00e9s A, Pizarro G, Gonz\u00e1lez-Montero J, Rojas C, Burotto M (2025) Targeting HIF-2\u03b1: the role of belzutifan in clear cell renal carcinoma management. Expert Rev Clin Pharmacol 18:17\u201327","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1710_CR99","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1158\/2159-8290.CD-19-0499","volume":"9","author":"L Vuong","year":"2019","unstructured":"Vuong L, Kotecha RR, Voss MH, Hakimi AA (2019) Tumor microenvironment dynamics in clear-cell renal cell carcinoma. Cancer Discov 9:1349\u20131357","journal-title":"Cancer Discov"},{"key":"1710_CR100","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.7150\/thno.105276","volume":"15","author":"H Wang","year":"2025","unstructured":"Wang H, Zhou F, Qin WQ, Yang Y, Li XJY, Liu RP (2025) Metabolic regulation of myeloid-derived suppressor cells in tumor immune microenvironment: targets and therapeutic strategies. Theranostics 15:2159\u20132184","journal-title":"Theranostics"},{"key":"1710_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105176","volume":"104","author":"JKM Wong","year":"2024","unstructured":"Wong JKM, McCulloch TR, Alim L, Omer N, Mehdi AM, Tuong ZK, Bonfim-Melo A, Chung E, Nicol A, Simpson F et al (2024) TGF-beta signalling limits effector function capacity of NK cell anti-tumour immunity in human bladder cancer. EBioMedicine 104:105176","journal-title":"EBioMedicine"},{"key":"1710_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00641-0","author":"FL Wu","year":"2021","unstructured":"Wu FL, Yang J, Liu JJ, Wang Y, Mu JT, Zeng QX, Deng SZ, Zhou HM (2021a) Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Signal Transduct Target Ther. https:\/\/doi.org\/10.1038\/s41392-021-00641-0","journal-title":"Signal Transduct Target Ther"},{"key":"1710_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.05.004","author":"ZY Wu","year":"2021","unstructured":"Wu ZY, Shi JY, Lai C, Li KW, Li KQ, Li ZH, Tang Z, Liu C, Xu KW (2021b) Clinicopathological significance and prognostic value of cancer-associated fibroblasts in prostate cancer patients. Urol Oncol Semin Orig Investig. https:\/\/doi.org\/10.1016\/j.urolonc.2021.05.004","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"1710_CR104","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.18632\/aging.203886","volume":"14","author":"B Xie","year":"2022","unstructured":"Xie B, Li KJ, Zhang H, Lai GC, Li DP, Zhong XN (2022) Identification and validation of an immune-related gene pairs signature for three urologic cancers. Aging-US 14:1429\u20131447","journal-title":"Aging-US"},{"key":"1710_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217793","author":"RC Yang","year":"2025","unstructured":"Yang RC, Wang SZ, Li ZC, Yin C, Huang W, Huang WR (2025) Patient-derived organoid co-culture systems as next-generation models for bladder cancer stem cell research. Cancer Lett. https:\/\/doi.org\/10.1016\/j.canlet.2025.217793","journal-title":"Cancer Lett"},{"key":"1710_CR106","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/pros.20877","volume":"69","author":"XP Yu","year":"2009","unstructured":"Yu XP, Wang YQ, Jiang M, Bierie B, Roy-Burman P, Shen MM, Taketo MM, Wills M, Matusik RJ (2009) Activation of \u03b2-Catenin in mouse prostate causes HGPIN and continuous prostate growth after castration. Prostate 69:249\u2013262","journal-title":"Prostate"},{"key":"1710_CR107","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00262-024-03675-9","volume":"73","author":"KX Yu","year":"2024","unstructured":"Yu KX, Yuan WJ, Wang HZ, Li YX (2024) Extracellular matrix stiffness and tumor-associated macrophage polarization: new fields affecting immune exclusion. Cancer Immunol Immunother 73:115","journal-title":"Cancer Immunol Immunother"},{"key":"1710_CR108","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01744-8","author":"ZN Yuan","year":"2023","unstructured":"Yuan ZN, Li YP, Zhang SF, Wang XY, Dou H, Yu X, Zhang ZR, Yang SS, Xiao M (2023) Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol Cancer. https:\/\/doi.org\/10.1186\/s12943-023-01744-8","journal-title":"Mol Cancer"},{"key":"1710_CR109","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1158\/2326-6066.CIR-19-0146","volume":"7","author":"H Zelba","year":"2019","unstructured":"Zelba H, Bedke J, Hennenlotter J, Mostb\u00f6ck S, Zettl M, Zichner T, Chandran A, Stenzl A, Rammensee HG, Gouttefangeas C (2019) PD-1 and LAG-3 dominate checkpoint receptor-mediated T-cell inhibition in renal cell carcinoma. Cancer Immunol Res 7:1891\u20131899","journal-title":"Cancer Immunol Res"},{"key":"1710_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1113378","author":"CX Zhang","year":"2023","unstructured":"Zhang CX, Fei YX, Wang H, Hu S, Liu C, Hu R, Du QM (2023a) CAFs orchestrates tumor immune microenvironment-a new target in cancer therapy? Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2023.1113378","journal-title":"Front Pharmacol"},{"key":"1710_CR111","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01860-5","author":"H Zhang","year":"2023","unstructured":"Zhang H, Yue XH, Chen Z, Liu C, Wu WT, Zhang N, Liu ZQ, Yang LP, Jiang Q, Cheng Q et al (2023b) Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials. Mol Cancer. https:\/\/doi.org\/10.1186\/s12943-023-01860-5","journal-title":"Mol Cancer"},{"key":"1710_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-024-02031-1","author":"DY Zheng","year":"2024","unstructured":"Zheng DY, Zhang Y, Yang SK, Su N, Bakhoum M, Zhang GL, Naderinezhad S, Mao ZM, Wang Z, Zhou T et al (2024) Androgen deprivation induces neuroendocrine phenotypes in prostate cancer cells through CREB1\/EZH2-mediated downregulation of REST. Cell Death Discov. https:\/\/doi.org\/10.1038\/s41420-024-02031-1","journal-title":"Cell Death Discov"},{"key":"1710_CR113","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","volume":"74","author":"Y Zhu","year":"2014","unstructured":"Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo JQ, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG (2014) CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 74:5057\u20135069","journal-title":"Cancer Res"}],"container-title":["Genes & Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13258-025-01710-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13258-025-01710-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13258-025-01710-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T20:08:44Z","timestamp":1770667724000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13258-025-01710-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":114,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1710"],"URL":"https:\/\/doi.org\/10.1007\/s13258-025-01710-2","relation":{},"ISSN":["1976-9571","2092-9293"],"issn-type":[{"value":"1976-9571","type":"print"},{"value":"2092-9293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"5 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All of authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}